BR9809078A - Peptìdeos sintéticos utilizáveis nos testes biológicos para a detecção das infecções devido aos vìrus hiv1 do grupo o - Google Patents

Peptìdeos sintéticos utilizáveis nos testes biológicos para a detecção das infecções devido aos vìrus hiv1 do grupo o

Info

Publication number
BR9809078A
BR9809078A BR9809078-0A BR9809078A BR9809078A BR 9809078 A BR9809078 A BR 9809078A BR 9809078 A BR9809078 A BR 9809078A BR 9809078 A BR9809078 A BR 9809078A
Authority
BR
Brazil
Prior art keywords
viruses
group
biological tests
hiv1
detection
Prior art date
Application number
BR9809078-0A
Other languages
English (en)
Other versions
BR9809078B1 (pt
BRPI9809078B8 (pt
Inventor
Denis Marie Bernard Chenebaux
Jean-Francois Hubert Delagneau
Stephane Jean Xavier Gadelle
Francois Yves Rieunier
Original Assignee
Pasteur Sanofi Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9809078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9704356A external-priority patent/FR2761993B1/fr
Priority claimed from FR9802212A external-priority patent/FR2775287B1/fr
Application filed by Pasteur Sanofi Diagnostics filed Critical Pasteur Sanofi Diagnostics
Publication of BR9809078A publication Critical patent/BR9809078A/pt
Publication of BR9809078B1 publication Critical patent/BR9809078B1/pt
Publication of BRPI9809078B8 publication Critical patent/BRPI9809078B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção: <B>"PEPTìDEOS SINTéTICOS UTILIZáVEIS NOS TESTES BIOLóGICOS PARA A DETECçãO DAS INFECçõES DEVIDO AOS VìRUS HIV1 DO GRUPO O"<D>. A invenção refere-se aos peptídeos sintéticos que encontram sua aplicação nos testes biológicos de detecção das infecções devido aos vírus HIV-1 do grupo O, seu processo de preparo, das composições e feixes contendo esses peptídeos, assim conforme os testes biológicos que utilizam esses peptídeos.
BRPI9809078A 1997-04-09 1998-04-06 peptídeo sintético utilizáveis nos testes biológicos para a detecção das infecções devido aos vírus hiv1 do grupo o, composição que os compreende, processo de imunodosagem in vitro e kit de diagnóstico. BRPI9809078B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9704356A FR2761993B1 (fr) 1997-04-09 1997-04-09 Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 groupe 0
FR9704356 1997-04-09
FR9802212A FR2775287B1 (fr) 1998-02-24 1998-02-24 Peptides synthetiques consensus utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 du groupe o
FR9802212 1998-02-24
PCT/FR1998/000691 WO1998045323A1 (fr) 1997-04-09 1998-04-06 Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih-1 du groupe o

Publications (3)

Publication Number Publication Date
BR9809078A true BR9809078A (pt) 2000-08-01
BR9809078B1 BR9809078B1 (pt) 2012-12-11
BRPI9809078B8 BRPI9809078B8 (pt) 2021-05-25

Family

ID=26233456

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9809078A BRPI9809078B8 (pt) 1997-04-09 1998-04-06 peptídeo sintético utilizáveis nos testes biológicos para a detecção das infecções devido aos vírus hiv1 do grupo o, composição que os compreende, processo de imunodosagem in vitro e kit de diagnóstico.

Country Status (20)

Country Link
US (2) US7053175B1 (pt)
EP (1) EP0973802B1 (pt)
JP (1) JP3560987B2 (pt)
KR (1) KR100451312B1 (pt)
CN (1) CN1215082C (pt)
AT (1) ATE343590T1 (pt)
AU (1) AU740231B2 (pt)
BR (1) BRPI9809078B8 (pt)
CA (1) CA2286344C (pt)
CZ (1) CZ300927B6 (pt)
DE (1) DE69836265T2 (pt)
ES (1) ES2275305T3 (pt)
IL (2) IL132166A0 (pt)
NO (1) NO329149B1 (pt)
NZ (1) NZ500015A (pt)
PL (1) PL194863B1 (pt)
PT (1) PT973802E (pt)
RU (1) RU2184742C2 (pt)
TR (1) TR199902757T2 (pt)
WO (1) WO1998045323A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045323A1 (fr) * 1997-04-09 1998-10-15 Pasteur Sanofi Diagnostics Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih-1 du groupe o
CA2290217C (en) * 1998-11-30 2010-01-12 Ortho-Clinical Diagnostics, Inc. Peptides for the detection of hiv-1 group o
FR2874017B1 (fr) 2004-08-06 2006-11-24 Bio Rad Pasteur Sa Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
US9658220B2 (en) 2012-06-22 2017-05-23 Bio-Rad Laboratories, Inc. Human factor XIII as a normalization control for immunoassays
CN112481246B (zh) * 2020-12-16 2022-03-29 熊猫乳品集团股份有限公司 一种生物活性多肽fspankkltpkky及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204259A (en) 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
CA2107732C (en) 1992-10-06 2003-04-08 Lutz G. Gurtler Retrovirus from the hiv group and its use
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
GB9410044D0 (en) * 1994-05-19 1994-07-06 Int Murex Tech Corp Assay
DE4430998A1 (de) 1994-07-25 1996-02-01 Boehringer Mannheim Gmbh Metallchelat-markierte Peptide
PT787191E (pt) * 1994-10-20 2007-12-06 Pasteur Institut Sequências nucleotídicas de antigénios retroviraisde vih do tipo (ou sub-tipo) o
DE19505262C2 (de) 1995-02-16 1998-06-18 Behring Diagnostics Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
FR2731013B1 (fr) 1995-02-27 1997-05-16 Inst Nat Sante Rech Med Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
WO1996027012A1 (en) 1995-03-02 1996-09-06 Akzo Nobel N.V. Specific hiv-1 group o antigens
US5569553A (en) 1995-03-08 1996-10-29 Wilson Greatbatch Ltd. Battery design for achieving end-of-life indication during electrical discharge
DE19622088A1 (de) 1996-05-31 1997-12-04 Boehringer Mannheim Gmbh Anti-HIV-Antikörper als Kontrollproben
WO1998045323A1 (fr) * 1997-04-09 1998-10-15 Pasteur Sanofi Diagnostics Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih-1 du groupe o
EP1003878A2 (en) 1997-07-18 2000-05-31 Innogenetics N.V. Hiv-1 group o antigens and uses thereof

Also Published As

Publication number Publication date
AU7338698A (en) 1998-10-30
US20060234213A1 (en) 2006-10-19
EP0973802A1 (fr) 2000-01-26
TR199902757T2 (xx) 2000-02-21
NO994929D0 (no) 1999-10-08
CA2286344C (fr) 2012-08-07
CZ300927B6 (cs) 2009-09-16
CN1215082C (zh) 2005-08-17
ES2275305T3 (es) 2007-06-01
BR9809078B1 (pt) 2012-12-11
CZ357599A3 (cs) 2000-06-14
IL132166A0 (en) 2001-03-19
RU2184742C2 (ru) 2002-07-10
DE69836265T2 (de) 2007-05-31
KR100451312B1 (ko) 2004-10-06
NO329149B1 (no) 2010-08-30
US7053175B1 (en) 2006-05-30
AU740231B2 (en) 2001-11-01
ATE343590T1 (de) 2006-11-15
PL336115A1 (en) 2000-06-05
DE69836265D1 (de) 2006-12-07
EP0973802B1 (fr) 2006-10-25
CN1256695A (zh) 2000-06-14
KR20010006216A (ko) 2001-01-26
JP2001519800A (ja) 2001-10-23
US7838001B2 (en) 2010-11-23
PT973802E (pt) 2007-01-31
PL194863B1 (pl) 2007-07-31
NZ500015A (en) 2001-06-29
NO994929L (no) 1999-12-08
JP3560987B2 (ja) 2004-09-02
WO1998045323A1 (fr) 1998-10-15
BRPI9809078B8 (pt) 2021-05-25
IL132166A (en) 2006-12-10
CA2286344A1 (fr) 1998-10-15

Similar Documents

Publication Publication Date Title
PT891420E (pt) Processos para a replicacao dos virus influenza numa cultura celular e os virus influenza que se podem obter atraves do processo
BR9812649A (pt) Compostos contendo anéis de seis membros, processo para sua preparação, e seu uso como medicamentos
EA199901031A1 (ru) Производные бензимидазола
BR9815112A (pt) Processo para a preparação de polìmeros sintéticos com teor de monÈmeros restantes muito baixo, produtos preparados a partir dos mesmos e seu emprego
BR9915013A (pt) Composto, uso dos mesmos, processo para preparar os mesmos, droga, e, método para detecção in vitro para inibidores parp
TR199901081T2 (xx) Y�ntem ve bu y�ntemde kullan�lan yeni bile�imler.
BR0007008A (pt) Dispositivo para a aplicação de um produto sobre as fibras queratìnicas, notadamente os cìlios ou as sobrancelhas
BR9811861A (pt) Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh)
BR9914514A (pt) Agentes para gomagem de papel aperfeiçoados e processos para fabricação dos agentes e gomagem de papel
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
BR9812363A (pt) Composição de dentifrìcio anticárie com diversos componentes, e, processo de remineralização de porções desmineralizadas das estruturas dentais
BR9809078A (pt) Peptìdeos sintéticos utilizáveis nos testes biológicos para a detecção das infecções devido aos vìrus hiv1 do grupo o
BR0111158A (pt) Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
BR9800913A (pt) Promotor de gene cdc25b, preparação e uso do mesmo.
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
ES2119747T3 (es) Metodo para la preparacion y purificacion de una mezcla de glicosfingolipidos libre de contaminacion por virus no convencionales.
BR9903250A (pt) Antìgenos e imunoanálises para diagnóstico da doença de chagas.
BR9705511A (pt) Tambor de roupa para uma máquina de tratamento de roupa e ferramenta para sua fabricação.
BR9801085A (pt) Processo para a preparação de moenomicina a.
BR9705456A (pt) Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm.
Schmidt et al. Hemagglutination and Hemagglutination-Inhibition with Adenovirus Type 12.
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
BR0107604A (pt) Pró-catalisador sólido, sistema catalisador, e, processo para a polimerização de pelo menos uma ou mais olefinas
MX170741B (es) Composicion de lavado equipo de prueba y su uso para determinar un antigeno viral del herpes simplex

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Free format text: REFERENTE A RPI 1782, CODIGO 25.4 - ITEM 71 - QUANTO AO NOME DO DEPOSITANTE.

B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIO-RAD INNOVATIONS (FR)

Free format text: NOME ALTERADO DE: BIO-RAD PASTEUR

B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]

Free format text: REPUBLICACAO DO DEFERIMENTO PARA CORRECAO DO TITULO

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/12/2012, OBSERVADAS AS DEMAIS CONDICOES LEGAIS.

B24B Patent annual fee: requirement for complementing annual fee
B24E Patent annual fee: resolution cancelled

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2264 DE 27/05/2014

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/1998 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 06/04/2018